FEG
KNSA icon

Financial Enhancement Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Financial Enhancement Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-31,391
Closed -$2.01M – 142
2026
Q2 		$2.01M Buy
+31,391
New +$1.63M 0.24% 71

Other funds holding KNSA

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Financial Enhancement Group's KNSA Position: Q3 2026 in Review

Financial Enhancement Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2026, closing a stake of 31,391 shares — an estimated $2.01M sold.

Financial Enhancement Group first reported a position in KNSA in Q2 2026 and held it in 1 quarter. The position peaked at $2.01M in Q2 2026. 8 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Financial Enhancement Group reported no remaining Kiniksa Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Financial Enhancement Group sold 31,391 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $2.01M.
  • Financial Enhancement Group first reported a position in Kiniksa Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Financial Enhancement Group's Kiniksa Pharmaceuticals position peaked at $2.01M in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Financial Enhancement Group's 13F filing for Q3 2026, filed 8 Oct 2026.